Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05965752 · ClinicalTrials.gov registry record · NA
RECOVER-NEURO: Platform Protocol to Measure the Effects of Cognitive Dysfunction Interventions on Long COVID Symptoms
A NA study, sponsored by Duke University.
- Completed
- Registry status
- NA
- Development phase
- 328
- Enrollment target
NCT05965752 is a NA study that has completed, run by Duke University. The registered enrollment target is 328 participants.
The verdict
NCT05965752, a NA study, has completed, sponsored by Duke University.
- COMPLETED
- Registry status
- NA
- Development phase
- 328 participants
- Enrollment target
Study Summary
This platform protocol is designed to be flexible so that it is suitable for a wide range of settings within health care systems, for remote settings, and in community settings where it can be integrated into COVID-19 programs and subsequent treatment plans. This protocol is a prospective, multi-center, multi-arm, randomized, controlled platform trial evaluating potential interventions for PASC-mediated cognitive dysfunction. The hypothesis is that PASC associated dysfunction in cognitive domains, such as executive function and attention, may be improved by interventions that selectively focus on enhancing those domains.
Interventions
- OTHER BrainHQ/Active Comparator Activity
- OTHER BrainHQ
- OTHER PASC CoRE
- DEVICE tDCS-active
- DEVICE tDCS-sham
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 328 participants |
| Start Date | 2023-09-01 |
| Est. Completion | 2024-06-10 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05965752
The ClinicalTrials.gov registry entry for NCT05965752 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 328 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Duke University, which has 1,725 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which BrainHQ/Active Comparator Activity is the first listed.
NCT05965752 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05965752 about?
NCT05965752 is a clinical study titled "RECOVER-NEURO: Platform Protocol to Measure the Effects of Cognitive Dysfunction Interventions on Long COVID Symptoms". This platform protocol is designed to be flexible so that it is suitable for a wide range of settings within health care systems, for remote settings, and in community settings where it can be integrated into COVID-19 programs and subsequent treatment plans. This protocol is a prospective, multi-ce...
What is the current status of trial NCT05965752?
This trial is currently completed. It is a NA study. The enrollment target is 328 participants. The study started on 2023-09-01. Estimated completion is 2024-06-10.
What interventions are being tested in trial NCT05965752?
The interventions under investigation include: BrainHQ/Active Comparator Activity (OTHER), BrainHQ (OTHER), PASC CoRE (OTHER), tDCS-active (DEVICE), tDCS-sham (DEVICE).
Who is sponsoring clinical trial NCT05965752?
This trial is sponsored by Duke University, which has 1,725 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.